Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Tamoxifen with Radiation for Newly Diagnosed Glioblastoma
NCT00006388Phase 2Completed
- Sponsor
- NRG Oncology
- Start
- Dec 2000
- Primary completion
- Oct 2003
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tamoxifen in glioblastoma (GBM), sponsored by NRG Oncology. Primary endpoint: Overall Survival at 18 months. Started Dec 2000; status: completed.
02
Drugs
tamoxifen
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00006388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006388.